Novartis has received a positive opinion supporting EU approval of Glivec as a post-surgery treatment for patients at significant risk of relapse following removal of gastrointestinal stromal tumors.
Ms Leonard said: “After having achieved my goal of successfully identifying and acquiring a FDA cleared, CLIA waived product that offers CLX the opportunity to become market leader
Mr Stout served most recently as president of pharmaceuticals at GlaxoSmithKline, where he was responsible for the company’s global pharmaceutical operations, from January 2003 to February 2008. Prior
Since 2001, Dr Werner has been a managing director and senior vice president of GlaxoSmithKline (GSK) and has served as CEO of the GSK Foundation until earlier this
Most recently, Mr DuFresne served as president and CEO of Pacgen Biopharmaceuticals. Prior to that, Mr DuFresne served as president and CEO of Zelos Therapeutics and ConjuChem and
The company has also appointed Mr Gallitano to serve on the compensation, nominating and corporate governance, and healthcare quality and access committees of the board. Mr Gallitano has
Osi Pharmaceuticals, a biotechnology company, and Genentech, have announced that Osi has submitted a supplemental new drug application to the FDA for the use of Tarceva as a
Financial Highlights: Increased sales of $1.0 million in our infectious disease product lines were partially offset by a decrease of $0.5 million in sales of Eclectica” as a
Ferring Pharmaceuticals, a specialty biopharmaceutical company, has launched Firmagon, a new treatment option in hormonal therapy for prostate cancer, in Europe. The European launch of Firmagon follows the
Takeda Pharmaceutical Company has filed a new drug application to the Ministry of Health, Labour and Welfare for Lampion for treatment of secondary eradication of Helicobacter pylori. According
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.